CT-322 + carboplatin + paclitaxel

CT-322 + carboplatin + paclitaxel is a combination regimen consisting of CT-322, carboplatin, and paclitaxel, under investigation as an antineoplastic therapy primarily in solid tumors. - **CT-322** is a pegylated Adnectin biologic, engineered from the tenth type III domain of human fibronectin, that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), thereby exerting anti-angiogenic and antitumor effects[1][3][7]. CT-322 blocks VEGF-induced phosphorylation of VEGFR-2, inhibiting downstream mitogen-activated protein kinase signaling, tumor angiogenesis, and microvessel density, and has shown anti-tumor activity in preclinical and early clinical models[1][3][7]. - **Carboplatin** and **paclitaxel** are standard-of-care cytotoxic drugs used widely in oncology. Carboplatin is a platinum-based agent that alkylates and crosslinks DNA, leading to apoptosis[8]. Paclitaxel stabilizes microtubules and inhibits cell division[8]. The rationale for combining CT-322 with carboplatin and paclitaxel is to block tumor angiogenesis (CT-322) while targeting the cancer cell population directly (carboplatin and paclitaxel), potentially increasing anti-tumor efficacy through dual mechanisms.

Other names

CT-322 + carboplatin + paclitaxel